COX-2-derived prostacyclin mediates opioid-induced late phase of preconditioning in isolated rat hearts

Am J Physiol Heart Circ Physiol. 2002 Dec;283(6):H2534-43. doi: 10.1152/ajpheart.00209.2002. Epub 2002 Aug 8.

Abstract

Opioids confer biphasic (early and late) cardioprotection against myocardial infarction by opening mitochondrial ATP-sensitive K(+) channels. It is unknown whether cyclooxygenase-2 (COX-2), which mediates ischemia-induced late preconditioning, also mediates opioid-induced cardioprotection. Isolated perfused rat hearts were subjected to 20 min of global ischemia followed by 20 min of reperfusion. BW-373U86 (BW), a delta-opioid receptor agonist, was administered 1, 12, or 24 h before death. Recovery of left ventricular developed pressure (LVDP) after ischemia-reperfusion improved when BW was administered 1 or 24 h before ischemia (control: 57 +/- 8, BW 1 h: 75 +/- 5, BW 24 h: 85 +/- 6%) but not when it was administered 12 h before (60 +/- 5%). Levels of 6-keto-PGF(1alpha) (a stable metabolite of PGI(2)) in coronary effluent after 20 min of reperfusion were higher with 24-h BW pretreatment than in controls (1,053 +/- 92 vs. 724 +/- 81 pg/ml), whereas 6-keto-PGF(1alpha) levels at baseline did not differ. Administration of a selective COX-2 inhibitor, NS-398, abolished the late phase of cardioprotection (recovery of LVDP, 53 +/- 8%) and attenuated the increase in PGI(2) (706 +/- 138 pg/ml) but did not block the early phase of cardioprotection. The selective COX-1 inhibitor SC-560 did not affect either phase of protection. Western immunoblotting revealed upregulation of PGI(2) synthase protein 24 h after BW administration without changes in COX-1 and COX-2 protein levels. In conclusion, the late (but not the early) phase of delta-opioid receptor-induced preconditioning is mediated by COX-2. A functional coupling between COX-2 and upregulated PGI(2) synthase appears to underlie this cardioprotective phenomenon in the rat.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / analysis
  • 6-Ketoprostaglandin F1 alpha / biosynthesis
  • Animals
  • Benzamides / pharmacology
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / pharmacology
  • Dose-Response Relationship, Drug
  • Epoprostenol / metabolism*
  • Heart / drug effects*
  • Heart / physiology*
  • In Vitro Techniques
  • Ischemic Preconditioning, Myocardial*
  • Isoenzymes / metabolism*
  • Male
  • Membrane Proteins
  • Myocardial Reperfusion
  • Myocardium / metabolism
  • Narcotics / pharmacology*
  • Nitrobenzenes / pharmacology
  • Piperazines / pharmacology
  • Prostaglandin-Endoperoxide Synthases / metabolism*
  • Pyrazoles / pharmacology
  • Rats
  • Rats, Inbred F344
  • Receptors, Opioid, delta / agonists
  • Sulfonamides / pharmacology
  • Ventricular Function, Left / drug effects
  • Ventricular Function, Left / physiology

Substances

  • Benzamides
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Membrane Proteins
  • Narcotics
  • Nitrobenzenes
  • Piperazines
  • Pyrazoles
  • Receptors, Opioid, delta
  • SC 560
  • Sulfonamides
  • N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
  • BW 373U86
  • 6-Ketoprostaglandin F1 alpha
  • Epoprostenol
  • Cyclooxygenase 1
  • Cyclooxygenase 2
  • Prostaglandin-Endoperoxide Synthases
  • Ptgs1 protein, rat